STP-707 is under clinical development by Sirnaomics and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase I drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STP-707’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STP-707 overview
STP-707 is under development for the treatment of cholangiocarcinoma, hepatocellular carcinoma, liver fibrosis, solid tumors, lung fibrosis, ovarian cancer, non-alcoholic steatohepatitis (NASH), metastatic cutaneous squamous cell carcinoma, pancreatic cancer, colon cancer, melanoma, liver metastases and non-small cell lung cancer. It is a systemic formulation of STP-705. It is administered intravenously and inhalational. The drug candidate acts by targeting transforming growth factor beta 1 (TGF beta 1) and cyclooxygenase-2. It is developed based on polypeptide nanoparticle (PNP) delivery platform.
It was also under development for primary sclerosing cholangitis.
Sirnaomics overview
Sirnaomics, is a healthcare service provider that discovers and develops therapeutics. The company’s pipeline products include STP705 treats cutaneous squamous cell carcinoma (IssCC) and basal cell carcinoma (BCC) ;STP707 targets multiple solid tumors; STP705 is for the treatment of fat remodeling; RV-1730 for covid 19; STP122G treats anticoagulation/thrombosis; STP125G targets hypertriglyceridemia; STP144G is for the treatment of complement mediated diseases. Sirnaomics offers product development, preclinical programs, clinical development services, among others. It has its presence in the US and China. Sirnaomics company is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of STP-707’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
